Thoracotomy and VATS Surgery in Local Non-Small-Cell Lung Cancer : Differences in Long-Term Health-Related Quality Of Life by Rauma, Ville et al.
Original StudyThoracotomy and VATS Surgery in Local
NoneSmall-Cell Lung Cancer: Differences in
Long-Term Health-Related Quality Of Life
Ville Rauma,1 Saana Andersson,1 Eric M. Robinson,2 Jari V. Räsänen,1
Harri Sintonen,3 Jarmo A. Salo,1 Ilkka K. Ilonen1
Abstract
Very long-term health-related quality of life (HRQoL) is an important end point in operated early stage non
esmall-cell lung cancer with good prognosis. The results for very long-term HRQoL after minimally invasive
video-assisted thoracoscopic surgery (VATS) has not been evaluated and compared to thoracotomy. Sur-
prisingly, inferior overall HRQoL was evident for patients operated with VATS, independent of preoperative
factors including age, comorbidities, and pulmonary function tests.
Background: As a result of routine low-dose computed tomographic screening, lung cancer is more frequently
diagnosed at earlier, operable stages of disease. In treating local nonesmall-cell lung cancer, video-assisted thor-
acoscopic surgery (VATS), a minimally invasive surgical approach, has replaced thoracotomy as the standard of care.
While short-term quality-of-life outcomes favor the use of VATS, the impact of VATS on long-term health-related
quality of life (HRQoL) is unknown. Patients and Methods: We studied patients who underwent lobectomy for the
treatment of nonesmall-cell lung cancer from January 2006 to January 2013 at a single institution (n ¼ 456). Patients
who underwent segmentectomy (n ¼ 27), who received neoadjuvant therapy (n ¼ 13), or who were found to have
clinical stage > T2 or > N0 disease (n ¼ 45) were excluded from analysis. At time of HRQoL assessment, 199 patients
were eligible for study and were mailed the generic HRQoL instrument 15D. Results: A total of 180 patients (90.5%)
replied; 92 respondents underwent VATS while 88 underwent open thoracotomy. The VATS group more often had
adenocarcinoma (P ¼ .006), and lymph node stations were sampled to a lesser extent (P ¼ .004); additionally, hospital
length of stay was shorter among patients undergoing VATS (P ¼ .001). No other clinical or pathologic differences
were observed between the 2 groups. Surprisingly, patients who underwent VATS scored signiﬁcantly lower on
HRQoL on the dimensions of breathing, speaking, usual activities, mental function, and vitality, and they reported a
lower total 15D score, which reﬂects overall quality of life (P < .05). Conclusion: In contrast to earlier short-term
reports, long-term quality-of-life measures are worse among patients who underwent VATS compared to
thoracotomy.
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Lung cancer is the leading cause of cancer death globally and is
among the leading cancers in overall total incidence.1 In Finland,
lung cancer is the leading cause of cancer-related death; 5-year-
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signiﬁcant proportion of the lung cancer burden from advanced
metastatic disease to earlier, treatable local disease. Low-dose
computed tomographic screening, for example, has been prospec-
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Thoracotomy and VATSsingle-view chest radiography.3 For patients diagnosed with early
stage operable disease, 5-year survival rates may exceed 50%.1
Additionally, with promising chemo- and radiotherapy strategies
and modern surgical interventions, the life expectancy of lung
cancer patients is further improving.2
In addition to improvements in prognosis or the quantity of
remaining life years, the quality of remaining life years is increasingly
viewed as an essential component in devising novel strategies for the
treatment of cancer.4 As a general trend in the ﬁeld of surgery,
minimally invasive methods are favored whenever suitable. Since its
introduction in the 1990s, video-assisted thoracoscopic surgery
(VATS) has gained a strong foothold.5 It provides oncologic efﬁcacy
similar to open thoracotomy,6,7 and even better perioperative sur-
vival.8 VATS patients encounter fewer perioperative complica-
tions8,9 and experience less postoperative pain.10 Thus, patients
with already deteriorated health reserves—such as patients with
poor preoperative lung functions11,12 and those with additional
comorbidities8—seem to beneﬁt from VATS. In consideration of
the abovementioned advantages and the lower overall cost,13 VATS
is now largely considered the standard of care in the surgical
treatment of local nonesmall-cell lung cancer (NSCLC).5
While numerous studies have associated VATS with better short-
term postoperative health-related quality of life (HRQoL),10,14,15
studies evaluating long-term HRQoL differences are scarce, and
to date only a few studies have evaluated the effect of surgical
treatment on HRQoL over a time period more than 2 years.16
To examine this matter, we assessed the long-term HRQoL mini-
mum 2 years after the operation among patients who underwent sur-
gery for local NSCLC in our clinic between the years 2006 and 2013.
Patients and Methods
Patients
We studied patients who underwent lobectomy for the treatment
of NSCLC from January 2006 to January 2013 at a single insti-
tution (n ¼ 456). Figure 1 summarizes the patient selection. Pa-
tients who underwent surgery from January 2006 to June 2009
received the HRQoL instrument in July 2011 (n ¼ 199), while
patients who underwent surgery between July 2009 and January
2013 (n ¼ 257) received their HRQoL instrument in May 2016. A
national registry provided information concerning mortality. At the
time of the HRQoL assessment, 79 patients from the ﬁrst group
and 93 patients from the second group had died. Thirteen patients
who received neoadjuvant therapy and 45 patients with advanced
disease (clinical stage  T3 or  N1) were also ineligible. Twenty-
seven patients who had undergone sublobar resection were further
excluded. In total, 199 patients were included in this study and sent
the 15D17 HRQoL instrument by mail. After 2 months, non-
respondents were contacted by phone and asked to either return the
survey by mail or answer it over the phone.
Disease was staged according to the 7th edition of the American
Joint Committee on Cancer tumor, node, metastasis classiﬁcation
system.18 The Charlson comorbidity index (CCI)19 was applied to
assess the extent of comorbidities from the medical records.
Surgical Techniques
Thoracotomy was performed through the muscle-sparing ante-
rolateral approach, and patients were scheduled for epidural painnical Lung Cancer Month 2019catheter preoperatively. The success rate of the epidural anesthesia
was not systematically recorded into electronic patient records.
VATS was introduced in our clinic in 2006 and was performed
almost uniformly through the 3-port approach.20 Local anesthetic
was applied before the incision was made. Additional ports were
placed at the discretion of the operating surgeon. All patients
postoperatively had a 28-F pleural catheter on active suction placed,
and all had access to specialized pain management service.
The decision between VATS or thoracotomy as the surgical
method was partially surgeon dependent and partially inﬂuenced by
many other factors, eg, the designated operating room, the gradual
implementation of VATS in our clinic, and the educational re-
quirements of the clinic’s residents. Surgeons did not have their own
patients, as the patients came from a single queue and were operated
in order. The universal health care system in Finland prevents so-
cioeconomic selection bias, as surgeons do not get paid on the basis
of the type of operations they perform, and patient fees do not differ
between the methods either.
Quality-of-Life Instrument
The 15D is a self-administered generic quality-of-life instrument
with 15 dimensions and a single index score, the 15D score, repre-
senting the overall quality of life. Each dimension has 5 ordinal levels,
from which the ﬁnal dimension level values and the 15D score can be
calculated using a set of population-based preference or utility weights.
Each dimension level value and the 15D score ranges from0 to1, with a
high score representing a good state of function and quality of life. A
minimal important difference in the 15D score is 0.015.21
Statistical Analysis
SPSS 22.0.0.0 software (IBM, Armonk, NY) was used to perform
statistical analysis. Results for continuous variables are provided as
mean (standard deviation) and for categorical variables as n (per-
centage). Independent sample t test served to compare parametric
and Mann-Whitney U test nonparametric continuous variables,
while the chi-square test was used to compare categorical variables.
Two-tailed P < .05 was considered signiﬁcant.




A total of 180 patients (90.5%) responded to the questionnaire
(71 of the earlier cohort and 109 of the later cohort). The groups
were combined for analysis. Of the respondents, 92 (51.1%) un-
derwent VATS and 88 (48.9%) underwent thoracotomy. There
were 4 conversions (4.0%); those patients were included in the
thoracotomy group for the analysis. The VATS group had a higher
response rate (94.8%) than the thoracotomy group (86.3%) (P ¼
.040). Table 1 summarizes preoperative patient demographics.
Table 2 describes peri- and postoperative patient and operational
characteristics. The overall mean and median ages for the
respondents were 65.81 (8.39) and 67 years, respectively. Adeno-
carcinoma was more common in the VATS group (81.5% vs.
59.1%; P ¼ .006), and they had on average fewer lymph node
stations sampled during the operation (P ¼ .004). Patients under-
going VATS were also discharged earlier with a shorter mean
Figure 1 Patient Flowchart
180 answered
A = Lobectomy, segmentectomy or wedge resec?on
B = Preopera?vely either T > 2 or N > 0.
456 pa?ents operated A between 1st Jan 2006 and 31st
Jan 2013
199 between 1.1.2006 -
30.6.2009
257 between 1.7.2009 -
31.1.2013
73 pa?ents received 15D in July 
2011
126 pa?ents received 15D in May 
2016
79 deceased
28 with too advanced disease B
6 receiving neoadjuvant therapy
17 with too advanced disease B
7 receiving neoadjuvant therapy
93 deceased
2 non-responders 17 non-responders
92 VATS lobectomies 88 thoracotomy 
lobectomies
13 sublobar resec?ons 14 sublobar resec?ons
Ville Rauma et alhospital length of stay of 6.4 (4.6) days versus 8.7 (5.2) days for the
thoracotomy group (P ¼ .001). The median hospital length of stay
was likewise shorter in the VATS group (5 days vs. 7 days). No
differences in follow-up time, age, sex distribution, CCI, percentageof forced expiratory volume in 1 second (FEV1%), percentage of
diffusing capacity of the lungs for carbon monoxide (DLCO%),
smoking status, clinical or pathologic stage, tumor location, adju-
vant therapy, or complication rate were observed between the 2Clinical Lung Cancer Month 2019 - 3





(N [ 88) P
Age (y), mean (SD) 66.9 (8.1) 64.7 (8.5) NS
Women 42 (45.7) 51 (58.0) NS
CCI NS
0 33 (35.9) 43 (48.9)
1 30 (32.6) 23 (26.1)
2 20 (21.7) 12 (13.6)
3 7 (7.6) 7 (8.0)
4 1 (1.1) 1 (1.1)
5 1 (1.1) 2 (2.3)
FEV1%,
a mean (SD) 79.0 (19.7) 79.4 (18.2) NS
DLCO%,b mean (SD) 76.4 (17.6) 77.5 (16.8) NS
Smoking Status NS
Smoker 73 (79.3) 73 (83.0)
Current smokerc 45 (48.9) 37 (42.0)
Never smoker 19 (20.7) 15 (17.0)
Smoking pack-years,d
mean (SD)
40.2 (23.0) 33.9 (21.5) NS
Clinical Stage NS
IA 68 (73.9) 56 (63.6)
IB 18 (19.6) 23 (26.1)
IIA 6 (6.5) 9 (10.2)
Data are presented as n (%) unless otherwise indicated.
Abbreviations: CCI ¼ charlson comorbidity index; DLCO% ¼ percentage of diffusing capacity of
lungs for carbon monoxide; FEV1% ¼ percentage of forced expiratory volume in 1 second;
NS ¼ not signiﬁcant; SD ¼ standard deviation; VATS ¼ video-assisted thoracoscopic surgery.
aPatients’ FEV1% value compared to predicted value.
bPatients’ DLCO% value compared to predicted value.
cAt time of operation.
dAmong smokers.






(N [ 88) P
Tumor Location NS
Right superior 40 (43.5) 22 (25.0)
Right inferior 20 (21.7) 30 (34.1)
Right medial 3 (3.3) 4 (4.5)
Left superior 16 (17.4) 18 (20.5)
Left inferior 13 (14.1) 14 (15.9)
Histology .006
Adenocarcinomaa 75 (81.5) 52 (59.1)
Squamous-cell carcinoma 16 (17.4) 32 (36.4)
Large-cell carcinoma 1 (1.1) 1 (1.1)
Other 0 3 (3.4)
Pathologic Stage NS
IA 60 (65.2) 53 (60.2)
IB 15 (16.3) 15 (17.0)
IIA 11 (12.0) 13 (14.8)
IIB 2 (2.2) 2 (2.3)
IIIA 4 (4.3) 5 (5.7)
No. of nodal stations
sampled, mean (SD)
3.5 (1.8) 4.5 (1.6) .004
Adjuvant therapyb 6 (6.5) 9 (10.2) NS
Hospital stay (d) 6.4 (4.6) 8.7 (5.2) .001
Complication 18 (19.6) 17 (19.3) NS
Progression 8 (8.7) 8 (9.1) NS
Follow-up (mo), mean (SD) 50.1 (14.7) 50.7 (11.4) NS
Data are presented as n (%) unless otherwise indicated.
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presence of no to low comorbidity (CCI 0-1) and high comorbidity
(CCI  2) (P ¼ .332).
Quality of Life
Figure 2 summarizes the HRQoL scores of the 2 groups. No
differences were identiﬁed on the dimensions of mobility, vision,
hearing, sleeping, eating, excretion, discomfort and symptoms,
depression, distress, and sexual activity (P > .05). The VATS group
scored both statistically and clinically signiﬁcantly lower on the
dimensions of breathing (0.637 vs. 0.719, P ¼ .030), speaking
(0.942 vs. 0.973, P ¼ .046), usual activities (0.746 vs. 0.821, P ¼
.030), mental function (0.818 vs. 0.917, P ¼ .001), vitality (0.767
vs. 0.824, P ¼ .049), and in the total 15D score (0.809 vs. 0.851,
P ¼ .028).
Discussion
In a retrospective study of 199 patients who underwent lobec-
tomy for surgical resection of early stage NSCLC, we report lower
long-term HRQoL in patients undergoing resection by VATS
versus thoracotomy. These results are in conﬂict with previous
short-term ﬁndings10,14,15 and with 2 previous long-term studies,
which also suggest HRQoL differences favoring VATS.22,23nical Lung Cancer Month 2019However, these latter studies of long-term HRQoL included only
51 and 33 patients. Nevertheless, our results are particularly strik-
ing, as one of the largest differences was observed on the dimension
of breathing, which directly contrast with previous studies empha-
sizing the positive effects of VATS on pulmonary function24 and in
patients with already decreased pulmonary function.11
Baseline differences in pulmonary function do not appear to
account for the observed HRQoL differences. The groups did not
differ preoperatively on FEV1% (P ¼ .826) or on DLCO% (P ¼
.658), suggesting differences resulting from the treatment. However,
previous studies have failed to consistently link pulmonary function
tests and subjective HRQoL.25 One study demonstrated a marginal
correlation between the preoperative percentage predicted transfer
factor of the lung for carbon monoxide (TLCO) value and the 6-
month postoperative global health status,26 while another study
found no correlation at all between the pulmonary function tests
and HRQoL.27 Thus, the relationship between baseline pulmonary
function tests and HRQoL differences remains unclear.
Another potential explanation is the distribution of comorbidities
between patient groups. Comorbidities seem to have a negative
relationship with postoperative HRQoL, especially when the patient
has more than one comorbid condition.16 However, as shown in
Figure 2 Comparison of 15D Proﬁles of Patient Groups. *Dimension With Both Statistically and Clinically Signiﬁcant Difference
Ville Rauma et alTable 1, the patient groups did not differ in preoperative CCI
distribution. As our clinical impression was that patients with
poorer health reservoirs were more likely to undergo VATS, we
found this result surprising. Originally CCI was developed to pre-
dict mortality, not HRQoL,19 and a study comparing 3 different
multimorbidity assessment instruments found CCI to have the
weakest explanatory power concerning HRQoL.28 Despite this,
another study of prostate cancer patients demonstrated a signiﬁcant,
yet relatively weak, association between CCI and long-term
HRQoL.29 A third study demonstrated a signiﬁcant association
between self-reported CCI and HRQoL, while CCI derived directly
from medical records failed to predict HRQoL.30 This makes sense
because patients are probably more likely to report diseases that
disturb their HRQoL.
Another potential explanation is the older age or mental age of
the patients who underwent VATS. While the age difference be-
tween the 2 groups did not reach statistical signiﬁcance (P ¼ .074),
a more comprehensive index of the impact of aging and on mental
age, such as a frailty index, might account for observations of worse
HRQoL in the VATS groups. Frailty, assessed by multidimensional
models, is a comprehensive concept for the evaluation of eligibility
for surgery, and it seems to have a strong predictive value at least on
survival.31 Of note, the greatest difference between the 2 groups was
on the dimension of mental function (0.818 vs. 0.917, P ¼ .001).
This observation may reﬂect underlying baseline differences in
frailty that we failed to capture, and that could explain differences in
HRQoL despite similar individual objective preoperative
measurements.
Differences in baseline clinical and pathologic characteristics were
observed for some features between the 2 groups. Adenocarcinomawas signiﬁcantly more common among VATS patients, while the
thoracotomy group had 2 times as many squamous-cell carcinomas.
Because squamous-cell carcinoma tends to have more often central,
and adenocarcinoma peripheral, lesions,1,32 this may bias the results
in some way—although the relationship with quality-of-life mea-
sures is not obvious. The possible effect that the observed difference
in the number of lymph node stations sampled could have on
HRQoL remains unclear, while oncologically there was no differ-
ence in the staging or disease progression between the groups.
Finally, another explanation for the observed differences in
HRQoL is differences in preoperative counseling between the
groups. While thoracotomy patients are told to expect postoperative
pain and at least early deterioration of their daily performance sta-
tus, VATS patients may be given a more positive impression con-
cerning the effects of the surgery on their HRQoL. This association
between the fulﬁllment of patient expectations and HRQoL gains
has been previously reported, for example, in total joint replacement
surgery. Patients with lower procedural expectations were more
likely to have their expectations fulﬁlled and to report greater gains
in HRQoL.33 This is also consistent with previous observations of
persistent pain after lung cancer surgery. One long-term report
found a slight reduction in baseline pain favoring VATS but no
difference between VATS and thoracotomy when considering the
impact of pain on daily activities.34 This latter negative result sug-
gests that patient assessments of quality of life are nested within
additional factors such as expectations of procedure beneﬁt and risk.
Our study has some limitations. The retrospective design and
lack of baseline data on HRQoL precluded identiﬁcation of actual
changes in HRQoL as a consequence of the surgical method chosen,
enabling only the comparison of HRQoL values at a single timeClinical Lung Cancer Month 2019 - 5
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for clarifying the potential impact of patient procedural expectations
as well as baseline differences in mental function or frailty between
the 2 groups. The 2-part collection of data may also predispose the
results to some temporal bias. Notably, the latter cohort had
signiﬁcantly longer interim follow-up period before HRQoL
assessment (mean 55.8 vs. 42.4 months, P ¼ .001). Nevertheless,
both cohorts had a similar percentage of VATS patients (48.4% vs.
49.3%), and HRQoL results were consistent across the 2 collection
periods—though some differences were only trending as a result of
smaller sample sizes.
The strengths of this study include the cohort size and response
rate. To our knowledge, this is the largest study of long-term
HRQoL outcomes in patients who underwent VATS versus tho-
racotomy for early stage resection. Moreover, our response rate
exceeded 90%, suggesting that our sample is highly representative.
Conclusion
We report the surprising result that patients undergoing VATS
had worse long-term HRQoL scores in several critical dimensions,
including breathing and overall 15D score. Further investigation is
necessary to clarify this unexpected result.
Clinical Practice Points
 Both thoracotomy and minimally invasive VATS approach for
early stage NSCLC are associated with decreased HRQoL in
dimensions dependent on physical activity.
 Pulmonary function tests are poor surrogates for predicting
postoperative HRQoL, and they should be used only in
perspective for predicting morbidity and mortality.
 For reasons not fully understood, patients operated with VATS
have inferior HRQoL. More studies are needed to assess the
causes for this ﬁnding, as this ﬁnding was unrelated to conven-
tional estimates of operability including: performance status,
patient age, CCI, or pulmonary function tests.Acknowledgments
This work was supported by the Foundation of the Finnish Anti-
Tuberculosis Association and by the Foundation of Väinö and Laina
Kivi. The authors thank Yvonne Sundström (Department of Gen-
eral Thoracic and Esophageal Surgery, Heart and Lung Center,
Helsinki University Central Hospital, Helsinki, Finland) for secre-
tarial assistance.
Disclosure
The authors have stated that they have no conﬂict of interest.
References
1. Brambilla E, Travis WD. Lung cancer. In: Stewart BW, Wild CP, eds. World
Cancer Report, 2014. Lyon, France: International Agency for Research on Cancer;
2014:350-61.
2. Finnish Cancer Registry, Available at: https://cancerregistry.ﬁ/statistics/cancer-
statistics/. Accessed: January 12, 2018.
3. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al.
Reduced lung-cancer mortality with low-dose computed tomographic screening.
N Engl J Med 2011; 365:395-409.
4. Rummans TA, Bostwick JM, Clark MM, Mayo Clinic Cancer Center Quality of
Life Working Group. Maintaining quality of life at the end of life. Mayo Clin Proc
2000; 75:1305-10.nical Lung Cancer Month 20195. Vannucci F, Gonzalez-Rivas D. Is VATS lobectomy standard of care for operable
nonesmall cell lung cancer? Lung Cancer 2016; 100:114-9.
6. Berry MF, D’Amico TA, Onaitis MW, Kelsey CR. Thoracoscopic approach to
lobectomy for lung cancer does not compromise oncologic efﬁcacy. Ann Thorac
Surg 2014; 98:197-202.
7. Licht PB, Jorgensen OD, Ladegaard L, Jakobsen E. A national study of nodal
upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer.
Ann Thorac Surg 2013; 96:943-9.
8. Falcoz PE, Puyraveau M, Thomas PA, et al. Video-assisted thoracoscopic surgery
versus open lobectomy for primary nonesmall-cell lung cancer: a propensity-
matched analysis of outcome from the European Society of Thoracic Surgeon
database. Eur J Cardiothorac Surg 2016; 49:602-9.
9. Nwogu CE, D’Cunha J, Pang H, et al. VATS lobectomy has better perioperative
outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB
140202 (Alliance). Ann Thorac Surg 2015; 99:399-405.
10. Bendixen M, Jorgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative
pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or
anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
Lancet Oncol 2016; 17:836-44.
11. Oparka J, Yan TD, Ryan E, Dunning J. Does video-assisted thoracic surgery
provide a safe alternative to conventional techniques in patients with limited
pulmonary function who are otherwise suitable for lung resection? Interact Car-
diovasc Thorac Surg 2013; 17:159-62.
12. Ceppa DP, Kosinski AS, Berry MF, et al. Thoracoscopic lobectomy has increasing
beneﬁt in patients with poor pulmonary function: a Society of Thoracic Surgeons
Database analysis. Ann Surg 2012; 256:487-93.
13. Swanson SJ, Meyers BF, Gunnarsson CL, et al. Video-assisted thoracoscopic lo-
bectomy is less costly and morbid than open lobectomy: a retrospective multi-
institutional database analysis. Ann Thorac Surg 2012; 93:1027-32.
14. Balduyck B, Hendriks J, Lauwers P, Van Schil P. Quality of life evolution after
lung cancer surgery: a prospective study in 100 patients. Lung Cancer 2007; 56:
423-31.
15. Handy JR Jr, Asaph JW, Douville EC, Ott GY, Grunkemeier GL, Wu Y. Does
video-assisted thoracoscopic lobectomy for lung cancer provide improved func-
tional outcomes compared with open lobectomy? Eur J Cardiothorac Surg 2010;
37:451-5.
16. Poghosyan H, Sheldon LK, Leveille SG, Cooley ME. Health-related quality of life
after surgical treatment in patients with non-small cell lung cancer: a systematic
review. Lung Cancer 2013; 81:11-26.
17. Sintonen H. The 15D instrument of health-related quality of life: properties and
applications. Ann Med 2001; 33:328-36.
18. Mirsadraee S, Oswal D, Alizadeh Y, Caulo A, van Beek EJ. The 7th lung cancer
TNM classiﬁcation and staging system: review of the changes and implications.
World J Radiol 2012; 4:128-34.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis 1987; 40:373-83.
20. HansenHJ, PetersenRH.Avideo-atlas of video-assisted thoracoscopic lobectomyusing
a standardized three-port anterior approach. Ann Cardiothorac Surg 2012; 1:104.
21. Alanne S, Roine RP, Räsänen P, Vainiola T, Sintonen H. Estimating the mini-
mum important change in the 15D scores. Qual Life Res 2015; 24:599-606.
22. Li WWL, Lee TW, Lam SSY, et al. Quality of life following lung cancer resection:
video-assisted thoracic surgery vs thoracotomy. Chest 2002; 122:584-9.
23. Aoki T, Tsuchida M, Hashimoto T, Saito M, Koike T, Hayashi J. Quality of life
after lung cancer surgery: video-assisted thoracic surgery versus thoracotomy. Heart
Lung Circ 2007; 16:285-9.
24. Kaseda S, Aoki T, Hangai N, Shimizu K. Better pulmonary function and prognosis
with video-assisted thoracic surgery than with thoracotomy. Ann Thorac Surg
2000; 70:1644-6.
25. Balduyck B, Hendriks J, Sardari Nia P, Lauwers P, Van Schil P. Quality of life
after lung cancer surgery: a review. Minerva Chir 2009; 64:655-63.
26. Win T, Sharples L, Wells FC, Ritchie AJ, Munday H, Laroche CM. Effect of lung
cancer surgery on quality of life. Thorax 2005; 60:234-8.
27. Brunelli A, Socci L, Refai M, Salati M, Xiume F, Sabbatini A. Quality of life before
and after major lung resection for lung cancer: a prospective follow-up analysis.
Ann Thorac Surg 2007; 84:410-6.
28. Fortin M, Hudon C, Dubois M, Almirall J, Lapointe L, Soubhi H. Comparative
assessment of three different indices of multimorbidity for studies on health-related
quality of life. Health Qual Life Outcomes 2005; 3:74.
29. Wahlgren T, Levitt S, Kowalski J, Nilsson S, Brandberg Y. Use of the Charlson
combined comorbidity index to predict postradiotherapy quality of life for prostate
cancer patients. Int J Radiat Oncol Biol Phys 2011; 81:997-1004.
30. Ng X, Low AHL, Thumboo J. Comparison of the Charlson Comorbidity Index
derived from self-report and medical record review in Asian patients with rheu-
matic diseases. Rheumatol Int 2015; 35:2005-11.
31. Kim S, Han H, Jung H, et al. Multidimensional frailty score for the prediction of
postoperative mortality risk. JAMA Surg 2014; 149:633-40.
32. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995; 75:191-202.
33. Gonzalez Saenz de Tejada M, Escobar A, Herrera C, Garcia L, Aizpuru F,
Sarasqueta C. Patient expectations and health-related quality of life outcomes
following total joint replacement. Value Health 2010; 13:447-54.
34. Wildgaard K, Ravn J, Nikolajsen L, Jakobsen E, Jensen TS, Kehlet H. Conse-
quences of persistent pain after lung cancer surgery: a nationwide questionnaire
study. Acta Anaesthesiol Scand 2011; 55:60-8.
